Specialty Pharma Journal Specialty, Precision & Technology
Basel, June 15, 2018 – Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden …
Tag Archives: Immune Thrombocytopenia
June, 2018
June, 2015
-
12 June
Novartis’ Promacta Approved for Children with a Rare Blood Disorder
US health regulators expanded approval of Novartis’ Promacta to treat children with a rare blood disorder. Novartis said that the US Food and Drug Administration (FDA) approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to …